Antibiotic resistance (AR) poses a significant global threat, jeopardizing modern medicine's capacity to treat bacterial infections.  While the clinical implications are widely understood, experimental challenges in addressing AR hinder effective mitigation strategies.  Research faces difficulties in accurately modeling the complex interplay of bacterial evolution, antibiotic exposure, and host immune responses *in vivo*.  Current *in vitro* models, while useful, often fail to capture the multifaceted nature of infection and the impact of the host microbiome.  Furthermore, translating pre-clinical findings to clinical efficacy remains a major hurdle, given the significant variability in patient responses and the heterogeneous nature of bacterial populations.  High-throughput screening for novel antibiotics is hampered by the limited chemical diversity of existing compounds and the inherent difficulties in identifying novel drug targets within resistant bacteria.  Finally, the ethical considerations surrounding the use of human subjects in infection studies, coupled with logistical challenges of conducting global surveillance, further complicate the experimental landscape.  Overcoming these challenges requires a multidisciplinary approach integrating diverse expertise from microbiology, immunology, chemistry, and bioinformatics.